Zobrazeno 1 - 10
of 87
pro vyhledávání: '"John K. Erban"'
Autor:
Hanyin Wang, John K. Erban
Publikováno v:
Case Reports in Hematology, Vol 2017 (2017)
We present the case of a 48-year-old female with acute onset altered mental status, who was found to have eosinophilia, elevated troponin, and embolic strokes. Extensive testing for autoimmune, infectious, and coronary artery etiologies was unremarka
Externí odkaz:
https://doaj.org/article/7bd359f8a6e34554b48e2f936d2e4fd7
Autor:
Daqin Mao, Hong Chang, Angie Mae Rodday, Hilal Hachem, John K. Erban, Karen Freund, Susan Parsons
Publikováno v:
Journal of Clinical and Translational Science, Vol 3, Pp 157-157 (2019)
OBJECTIVES/SPECIFIC AIMS: (1) To evaluate the association of patient and clinical factors with adherence to adjuvant hormone therapy (HT). (2) To examine the association of HT-related symptoms and the extent of remediation with early discontinuation
Externí odkaz:
https://doaj.org/article/a291510875d7435baf4585c965df20ac
Breast Cancer:Over the course of the last decade, the treatment of breast cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment
Autor:
Rachel J. Buchsbaum, Abhigna Kodali, Preethi John, Raveendhara R. Bannuru, John K. Erban, Mikala C. Osani
Publikováno v:
Clinical Breast Cancer. 21:e22-e37
Background There are several regimens recommended by the National Comprehensive Cancer Network (NCCN) for HER2-negative operable breast cancer. To our knowledge, no trials have yet been performed comparing these regimens head to head. We performed a
Autor:
Gabriele Zoppoli, William Audeh, Theodora Goulioti, David Cameron, Iain R. Macpherson, Marco Colleoni, Antonino Musolino, Luis Manso, Audrey Mailliez, Evangelia Razis, Andrew Tutt, Virginie Adam, Peter Vuylsteke, John K. Erban, Michail Ignatiadis, Kai Yu Jen, István Láng, Bella Kaufman, Aafke H. Honkoop, Konstantinos Tryfonidis, Saskia Litière, Oskar T. Johannsson, Judith Balmaña, Olivier Tredan, Susan Ellard, Nicholas C. Turner, María José Juan-Fita, Lori J. Goldstein, C. Poncet
Publikováno v:
Clinical cancer research, 27 (20
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Clin Cancer Res
2021, ' Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-21-0310
Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm) advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gBRCAm and HER2-negative adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a1bfde4ac52e52c38e495f34c523cc
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/333689
Autor:
Newell E. McElwee, Peter K. Honig, Norman Stockbridge, Harry P. Selker, Hans-Georg Eichler, Kenneth I. Kaitin, Theodora Cohen, John K. Erban, Vicki L. Seyfert-Margolis, Willard H. Dere, Kenneth A. Oye, Ralph B. D'Agostino
Publikováno v:
Clinical Pharmacology and Therapeutics
Efficacy trials, designed to gain regulatory marketing approval, evaluate drugs in optimally selected patients under advantageous conditions for relatively short time periods. Effectiveness trials, designed to evaluate use in usual practice, assess t
Autor:
Anastassios G. Pittas, Michael R. Lewis, Ellen M Vickery, Jason Nelson, Patricia Sheehan, Rowena J. Dolor, Ranee Chatterjee, Paul J. Fuss, John K. Erban, Erin S. LeBlanc, Sangeeta R. Kashyap, Karen C. Johnson
Publikováno v:
Curr Dev Nutr
OBJECTIVES: We sought to determine if, compared to placebo, vitamin D supplementation reduces risk of incident cancer and precancerous lesions in a cohort of overweight/obese adults with prediabetes. METHODS: The D2d cancer outcomes study (D2dCA) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81383c07676e85a0e380d376c8ee143
https://europepmc.org/articles/PMC7259148/
https://europepmc.org/articles/PMC7259148/
Autor:
Danai Dima, Hilal Hachem, John K. Erban, Karen M. Freund, Susan K. Parsons, Joshua Dower, Hong Chang, Daqin Mao, Michael Wismer
Publikováno v:
Breast cancer research and treatment. 184(3)
To investigate predictors of treatment interruption and early discontinuation of adjuvant hormonal therapy (HT) in a retrospective cohort of women with newly diagnosed hormone receptor-positive (HR +) breast cancer. Eligible cases were identified fro
Autor:
Stephen P. Naber, Roger A. Graham, K Patel, John K. Erban, Lillian Chen, Abhishek Chatterjee, Michael M. Jonczyk
Publikováno v:
Cancer Research. 78:P4-13
Purpose Breast conservation has become the mainstay of surgical management for early stage breast cancer. Large volume displacement oncoplastic surgery (LVOS) uses reconstructive mastopexy and breast reduction techniques to allow for larger oncologic
Autor:
Abhishek Chatterjee, John K. Erban
Publikováno v:
Gland Surgery. 6:119-124
The complexity of managing early stage breast cancer is well known. Optimal treatment is increasingly multidisciplinary and in the modern era informed by sophisticated molecular tools to help select and guide therapy. Major phase III trials have dete